IO Biotech Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

IO Biotech wird ein jährliches Gewinn- und Umsatzwachstum von 4.5% bzw. 77.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 25.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -217.7% betragen.

Wichtige Informationen

4.5%

Wachstumsrate der Gewinne

25.1%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.5%
Wachstumsrate der Einnahmen	77.8%
Zukünftige Eigenkapitalrendite	-217.7%
Analystenabdeckung	Low
Zuletzt aktualisiert	13 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:IOBT - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	23	-127	-102	N/A	4
12/31/2025	N/A	-113	-96	N/A	4
12/31/2024	N/A	-90	-80	N/A	4
9/30/2024	N/A	-90	-86	-86	N/A
6/30/2024	N/A	-88	-81	-81	N/A
3/31/2024	N/A	-88	-82	-82	N/A
12/31/2023	N/A	-86	-72	-72	N/A
9/30/2023	N/A	-80	-62	-61	N/A
6/30/2023	N/A	-74	-59	-59	N/A
3/31/2023	N/A	-71	-54	-54	N/A
12/31/2022	N/A	-71	-60	-60	N/A
9/30/2022	N/A	-74	-67	-66	N/A
6/30/2022	N/A	-65	-62	-61	N/A
3/31/2022	N/A	-87	-58	-58	N/A
12/31/2021	N/A	-75	-41	-41	N/A
9/30/2021	N/A	-56	-25	-24	N/A
6/30/2021	N/A	-54	-18	-18	N/A
3/31/2021	N/A	-17	-11	-11	N/A
12/31/2020	N/A	-15	-10	-10	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: IOBT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: IOBT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: IOBT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: IOBT wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: IOBT wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: IOBT wird voraussichtlich in 3 Jahren unrentabel sein.

IO Biotech Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 13% to US$8.50

Price target decreased by 15% to US$9.67

Price target decreased to US$17.50

Recent updates

IO Biotech, Inc. Announces Data from the NSCLC Cohort in the Phase 2 Basket Trial of IO102-IO103

IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-Line Treatment of Advanced Head and Neck Cancer

Price target decreased by 13% to US$8.50

IO Biotech, Inc. Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

New major risk - Financial position

New minor risk - Share price stability

We're A Little Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

IO Biotech, Inc. Announces Resignation of Jack Nielsen as Member of the Board of Directors

IO Biotech, Inc., Annual General Meeting, Jun 06, 2024

New minor risk - Market cap size

IO Biotech Announces Marjan Shamsaei as Senior Vice President

IO Biotech, Inc. Presents New Data At Aacr 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, Io102-Io103

IO Biotech, Inc. Appoints Faiçal Miyara as Chief Business Officer

IO Biotech Announces Acceptance of Abstract to Be Presented at the 2024 American Association for Cancer Research Annual Meeting

New major risk - Revenue and earnings growth

New minor risk - Market cap size

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

High number of new directors

IO Biotech Appoints Helen Collins, Md, to Its Board of Directors

IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma

New minor risk - Share price stability

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

Price target decreased by 15% to US$9.67

IO Biotech, Inc. Appoints Heidi Hunter to Its Board of Directors

IO Biotech, Inc. announced that it expects to receive $75.057935 million in funding from a group of investors

IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial At University of California Davis Comprehensive Cancer Center

IO Biotech, Inc. Announces Executive Changes

New minor risk - Share price stability

IO Biotech Announces Achievement of Significant Phase 3 Clinical Trial Recruitment Milestone

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

IO Biotech, Inc. Appoints Christine Richter as Senior Vice President, Commercial and Program Lead

Chief Financial Officer recently bought US$58k worth of stock

IO Biotech Appoints Devin Smith as General Counsel and Chief Compliance Officer

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

Price target decreased to US$17.50

IO Biotech, Inc. Announces Appointment of Amy Sullivan as Chief Financial Officer

IO Biotech names new CFO

We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

IO Biotech GAAP EPS of -$0.64

We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

IO Biotech Announces Initiation of Phase 3 Combination Trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as First-Line Treatment in Advanced Melanoma

IO Biotech, Inc. Announces Executive Changes

High number of new directors

High number of new directors

IO Biotech, Inc. Announces its Two Directors Not Stand for Re-Election

IO Biotech Announces Presentation of New Data from MM1636 Phase 1/2 Clinical Trial Presented at 2022 AACR Annual Meeting

IO Biotech, Inc. Announces Appointment of David V. Smith to Board of Directors

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken